A Randomized, Double-Blind, Phase 3b Study to Evaluate Effects of Aspirin or Dose Titration on Flushing and Gastrointestinal Events Following Oral Administration of BG00012 Dosed at 240 mg BID

Trial Profile

A Randomized, Double-Blind, Phase 3b Study to Evaluate Effects of Aspirin or Dose Titration on Flushing and Gastrointestinal Events Following Oral Administration of BG00012 Dosed at 240 mg BID

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jun 2016

At a glance

  • Drugs Dimethyl fumarate (Primary) ; Aspirin
  • Indications Multiple sclerosis; Rheumatoid arthritis; Thrombosis
  • Focus Adverse reactions; Registrational
  • Sponsors Biogen Idec
  • Most Recent Events

    • 22 Apr 2013 Actual end date changed from Aug 2012 to Oct 2012 as reported by ClinicalTrials.gov.
    • 01 Aug 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Apr 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top